Načítá se...
Pazopanib in advanced soft tissue sarcomas
Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular endothelial growth factor receptors, preclinical work indicates that pazopanib...
Uloženo v:
| Vydáno v: | Signal Transduct Target Ther |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group UK
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6522548/ https://ncbi.nlm.nih.gov/pubmed/31123606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-019-0049-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|